Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation

Trial Profile

Single center, double-blind, randomized, placebo-controlled, two-period/two-treatment crossover, proof-of-mechanism study investigating the effect of miglustat on the nasal potential difference in adult patients with cystic fibrosis homozygous for the F508del mutation

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Miglustat (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms MIGLUSTAT-CF
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 16 Mar 2018 Status changed from recruiting to completed.
    • 31 Jul 2016 Planned End Date changed from 1 Aug 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top